Abstract. Recombinant 
bolus of 75 \g=m\g/kg to 10 patients with Laron (1, 2) . It is character¬ ized by high levels of circulating hGH and very low levels of IGF-I (3, 4) . The pathogenesis has been found to reside in the GH receptors (5), resulting from partial deletions of the extracellular part of the gene for this receptor (6, 7) . This defect leads to an inability for endogenous IGF-I synthesis (3) . The recent availability of recombinant IGF-I (rIGF-I) made possible the initiation of trials with IGF-I in this patient population (8) as well as in healthy adults (9 (10) . Since rIGF-I (Fujisawa, Japan, Lot 144770 K) (11) is twice as potent as the kit standard, the values following IGF-I injection were corrected accordingly. The sensitiv¬ ity of the assay was 2 nmol/1 and the intra-and inter-assay variations were 3.5 and 8.8%, respectively.
Plasma GHRH was extracted from 2 ml plasma using SEP PAK C-18 cartridges (Waters, USA) and acetonitrile acetic acid as eluant. (Sigma, USA) 125I-GHRH(l-44), and homologous antiserum (Amersham, UK) were used as previously described (12) . The sensi¬ tivity of the assay was 1.2 pmol/1 and inter-and intra-assay variations were 10 and 17%, respectively.
Plasma hGH was determined by a double-antibody modification of the RIA described by Laron 8c Mann¬ heimer (13) 
Discussion
The present investigation sheds new light on the role played by circulating IGF-I in the feedback mechanism of hGH and GHRH. The experimental set up was an acute injection of recombinant IGF-I followed by blood sampling over a period of two hours in two groups of subjects: patients with he-reditary IGF-I deficiency, i.e. LTD, and normal controls. Despite much lower initial serum IGF-I levels in the LTD patients, as expected (3, 4) (19) .
It is of note that the marked increase in plasma hGH starting about 15 min after the iv injection of IGF-I occurs concomitantly with the decrease in GHRH levels and is therefore not mediated by this hormone. It can be explained by the IGF-I-induced hypoglycemia, but is of much greater extent than that usually observed after insulin hypoglycemia in young children and adults (20) . A similar rebound elevation of hGH has been observed after stopping a somatostatin infusion in LTD patients (21) as well as in acromegalic patients (22) .
In view of the above findings it is proposed that 
